10x Genomics (TXG) Reports In-Line Q1 EPS, provides guidance

10x Genomics (NASDAQ: TXG) reported Q1 EPS of ($0.50), in-line with the analyst estimate of ($0.50). Revenue for the quarter came in at $141 million versus the consensus estimate of $142.24 million.

GUIDANCE:

10x Genomics sees FY2024 revenue of $670-690 million, versus the consensus of $677.8 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• AeroVironment restates quarterly financials, citing $89M goodwill error
• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight